O	0	1	[	[	(	O
O	1	11	Prognostic	Prognostic	JJ	B-NP
O	12	24	significance	significance	NN	I-NP
O	25	27	of	of	IN	B-PP
B-Cell	28	36	cellular	cellular	JJ	B-NP
O	37	45	vascular	vascular	JJ	I-NP
O	46	57	endothelial	endothelial	JJ	I-NP
O	58	64	growth	growth	NN	I-NP
O	65	71	factor	factor	NN	I-NP
O	72	73	(	(	(	O
O	73	77	VEGF	VEGF	NN	B-NP
O	77	78	)	)	)	O
O	79	89	expression	expression	NN	B-NP
O	90	92	in	in	IN	B-PP
O	93	96	the	the	DT	B-NP
O	97	103	course	course	NN	I-NP
O	104	106	of	of	IN	B-PP
B-Cancer	107	114	chronic	chronic	JJ	B-NP
I-Cancer	115	122	myeloid	myeloid	JJ	I-NP
I-Cancer	123	132	leukaemia	leukaemia	NN	I-NP
O	132	133	]	]	)	O

O	134	146	INTRODUCTION	INTRODUCTION	NN	B-NP
O	146	147	:	:	:	O
O	148	157	Increased	Increase	VBN	B-NP
O	158	170	angiogenesis	angiogenesis	NN	I-NP
O	171	173	in	in	IN	B-PP
B-Multi-tissue_structure	174	178	bone	bone	NN	B-NP
I-Multi-tissue_structure	179	185	marrow	marrow	NN	I-NP
O	186	188	is	be	VBZ	B-VP
O	189	192	one	one	CD	B-NP
O	193	195	of	of	IN	B-PP
O	196	199	the	the	DT	B-NP
O	200	215	characteristics	characteristic	NNS	I-NP
O	216	218	of	of	IN	B-PP
B-Cancer	219	226	chronic	chronic	JJ	B-NP
I-Cancer	227	234	myeloid	myeloid	JJ	I-NP
I-Cancer	235	244	leukaemia	leukaemia	NN	I-NP
O	245	246	(	(	(	O
B-Cancer	246	249	CML	CML	NN	B-NP
O	249	250	)	)	)	O
O	250	251	,	,	,	O
O	252	253	a	a	DT	B-NP
O	254	260	clonal	clonal	JJ	I-NP
O	261	279	myeloproliferative	myeloproliferative	JJ	I-NP
O	280	288	disorder	disorder	NN	I-NP
O	289	293	that	that	WDT	B-NP
O	294	303	expresses	express	VBZ	B-VP
O	304	305	a	a	DT	B-NP
O	306	314	chimeric	chimeric	JJ	I-NP
O	315	318	bcr	bcr	NN	I-NP
O	318	319	/	/	SYM	B-VP
O	319	322	abl	abl	NN	B-NP
O	323	330	protein	protein	NN	I-NP
O	330	331	.	.	.	O

O	332	340	Vascular	Vascular	JJ	B-NP
O	341	352	endothelial	endothelial	JJ	I-NP
O	353	359	growth	growth	NN	I-NP
O	360	366	factor	factor	NN	I-NP
O	367	368	(	(	(	O
O	368	372	VEGF	VEGF	NN	B-NP
O	372	373	)	)	)	O
O	374	376	is	be	VBZ	B-VP
O	377	380	one	one	CD	B-NP
O	381	383	of	of	IN	B-PP
O	384	387	the	the	DT	B-NP
O	388	392	most	most	RBS	I-NP
O	393	399	potent	potent	JJ	I-NP
O	400	403	and	and	CC	O
O	404	405	a	a	DT	B-NP
O	406	414	specific	specific	JJ	I-NP
O	415	424	regulator	regulator	NN	I-NP
O	425	427	of	of	IN	B-PP
O	428	440	angiogenesis	angiogenesis	NN	B-NP
O	441	446	which	which	WDT	B-NP
O	447	458	principally	principally	RB	B-ADVP
O	459	466	targets	target	VBZ	B-VP
B-Cell	467	478	endothelial	endothelial	JJ	B-NP
I-Cell	479	484	cells	cell	NNS	I-NP
O	485	488	and	and	CC	O
O	489	498	regulates	regulate	VBZ	B-VP
O	499	506	several	several	JJ	B-NP
O	507	509	of	of	IN	B-PP
O	510	515	their	their	PRP$	B-NP
O	516	525	functions	function	NNS	I-NP
O	525	526	,	,	,	O
O	527	536	including	include	VBG	B-PP
O	537	548	mitogenesis	mitogenesis	NN	B-NP
O	548	549	,	,	,	I-NP
O	550	562	permeability	permeability	NN	I-NP
O	563	566	and	and	CC	I-NP
O	567	576	migration	migration	NN	I-NP
O	576	577	.	.	.	O

O	578	581	The	The	DT	B-NP
O	582	588	impact	impact	NN	I-NP
O	589	591	of	of	IN	B-PP
O	592	600	elevated	elevated	JJ	B-NP
O	601	605	VEGF	VEGF	NN	I-NP
O	606	616	expression	expression	NN	I-NP
O	617	619	on	on	IN	B-PP
O	620	623	the	the	DT	B-NP
O	624	630	course	course	NN	I-NP
O	631	633	of	of	IN	B-PP
B-Cancer	634	641	chronic	chronic	JJ	B-NP
I-Cancer	642	649	myeloid	myeloid	JJ	I-NP
I-Cancer	650	659	leukaemia	leukaemia	NN	I-NP
O	660	662	is	be	VBZ	B-VP
O	663	670	unknown	unknown	JJ	B-ADJP
O	670	671	.	.	.	O

O	672	681	OBJECTIVE	OBJECTIVE	NN	B-NP
O	681	682	:	:	:	O
O	683	686	The	The	DT	B-NP
O	687	690	aim	aim	NN	I-NP
O	691	693	of	of	IN	B-PP
O	694	698	this	this	DT	B-NP
O	699	704	study	study	NN	I-NP
O	705	708	was	be	VBD	B-VP
O	709	712	the	the	DT	B-NP
O	713	719	follow	follow	VB	I-NP
O	719	720	-	-	HYPH	B-VP
O	720	722	up	up	RP	B-PRT
O	723	725	of	of	IN	B-PP
O	726	730	VEGF	VEGF	NN	B-NP
O	731	741	expression	expression	NN	I-NP
O	742	748	during	during	IN	B-PP
O	749	752	the	the	DT	B-NP
O	753	759	course	course	NN	I-NP
O	760	762	of	of	IN	B-PP
B-Cancer	763	766	CML	CML	NN	B-NP
O	766	767	.	.	.	O

O	768	775	METHODS	METHODS	NNS	B-NP
O	775	776	:	:	:	O
O	777	779	We	We	PRP	B-NP
O	780	787	studied	study	VBD	B-VP
O	788	792	VEGF	VEGF	NN	B-NP
O	793	803	expression	expression	NN	I-NP
O	804	806	of	of	IN	B-PP
O	807	809	85	85	CD	B-NP
B-Cancer	810	813	CML	CML	NN	I-NP
O	814	822	patients	patient	NNS	I-NP
O	823	824	(	(	(	O
O	824	830	median	median	JJ	B-NP
O	831	834	age	age	NN	I-NP
O	835	837	50	50	CD	B-NP
O	838	843	years	year	NNS	I-NP
O	843	844	,	,	,	O
O	845	850	range	range	NN	B-NP
O	851	853	16	16	CD	I-NP
O	853	854	-	-	HYPH	O
O	854	856	75	75	CD	B-NP
O	857	862	years	year	NNS	I-NP
O	862	863	)	)	)	O
O	863	864	.	.	.	O

O	865	867	At	At	IN	B-PP
O	868	871	the	the	DT	B-NP
O	872	884	commencement	commencement	NN	I-NP
O	885	887	of	of	IN	B-PP
O	888	891	the	the	DT	B-NP
O	892	897	study	study	NN	I-NP
O	897	898	,	,	,	O
O	899	901	29	29	CD	B-NP
O	902	910	patients	patient	NNS	I-NP
O	911	915	were	be	VBD	B-VP
O	916	918	in	in	IN	B-PP
O	919	926	chronic	chronic	JJ	B-NP
O	927	932	phase	phase	NN	I-NP
O	933	934	(	(	(	O
O	934	936	CP	CP	NN	B-NP
O	936	937	)	)	)	O
O	937	938	,	,	,	O
O	939	941	25	25	CD	B-NP
O	942	944	in	in	IN	B-PP
O	945	947	an	an	DT	B-NP
O	948	959	accelerated	accelerate	VBN	I-NP
O	960	965	phase	phase	NN	I-NP
O	966	967	(	(	(	O
O	967	969	AP	AP	NN	B-NP
O	969	970	)	)	)	O
O	970	971	,	,	,	O
O	972	975	and	and	CC	O
O	976	978	31	31	CD	B-NP
O	979	981	in	in	IN	B-PP
O	982	985	the	the	DT	B-NP
O	986	991	blast	blast	NN	I-NP
O	992	998	crisis	crisis	NN	I-NP
O	999	1000	(	(	(	O
O	1000	1002	BC	BC	NN	B-NP
O	1002	1003	)	)	)	O
O	1003	1004	.	.	.	O

O	1005	1008	The	The	DT	B-NP
O	1009	1017	temporal	temporal	JJ	I-NP
O	1018	1028	expression	expression	NN	I-NP
O	1029	1030	(	(	(	O
O	1030	1040	percentage	percentage	NN	B-NP
O	1041	1051	positivity	positivity	NN	I-NP
O	1052	1055	per	per	IN	B-PP
O	1056	1060	1000	1000	CD	B-NP
O	1061	1069	analysed	analyse	VBN	I-NP
B-Cell	1070	1075	cells	cell	NNS	I-NP
O	1075	1076	)	)	)	O
O	1077	1081	VEGF	VEGF	NN	B-NP
O	1082	1090	proteins	protein	NNS	I-NP
O	1091	1095	over	over	IN	B-PP
O	1096	1099	the	the	DT	B-NP
O	1100	1106	course	course	NN	I-NP
O	1107	1109	of	of	IN	B-PP
B-Cancer	1110	1113	CML	CML	NN	B-NP
O	1114	1118	were	be	VBD	B-VP
O	1119	1126	studied	study	VBN	I-VP
O	1127	1132	using	use	VBG	B-VP
O	1133	1136	the	the	DT	B-NP
O	1137	1156	immunohistochemical	immunohistochemical	JJ	I-NP
O	1157	1166	technique	technique	NN	I-NP
O	1167	1176	utilizing	utilize	VBG	B-VP
O	1177	1185	relevant	relevant	JJ	B-NP
O	1186	1196	monoclonal	monoclonal	JJ	I-NP
O	1197	1207	antibodies	antibody	NNS	I-NP
O	1207	1208	.	.	.	O

O	1209	1211	It	It	PRP	B-NP
O	1212	1215	was	be	VBD	B-VP
O	1216	1226	correlated	correlate	VBN	I-VP
O	1227	1231	with	with	IN	B-PP
O	1232	1235	the	the	DT	B-NP
O	1236	1246	laboratory	laboratory	NN	I-NP
O	1247	1248	(	(	(	O
O	1248	1250	Hb	Hb	NN	B-NP
O	1250	1251	,	,	,	O
B-Cell	1252	1255	WBC	WBC	NN	B-NP
O	1256	1259	and	and	CC	I-NP
B-Cell	1260	1268	platelet	platelet	NN	I-NP
O	1269	1275	counts	count	NNS	I-NP
O	1275	1276	,	,	,	O
O	1277	1280	and	and	CC	O
O	1281	1284	the	the	DT	B-NP
O	1285	1295	percentage	percentage	NN	I-NP
O	1296	1298	of	of	IN	B-PP
O	1299	1305	blasts	blast	NNS	B-NP
O	1305	1306	)	)	)	O
O	1307	1310	and	and	CC	O
O	1311	1319	clinical	clinical	JJ	B-NP
O	1320	1330	parameters	parameter	NNS	I-NP
O	1331	1332	(	(	(	O
O	1332	1344	organomegaly	organomegaly	NN	B-NP
O	1344	1345	,	,	,	O
O	1346	1354	duration	duration	NN	B-NP
O	1355	1357	of	of	IN	B-PP
O	1358	1360	CP	CP	NN	B-NP
O	1360	1361	,	,	,	O
O	1362	1364	AP	AP	NN	B-NP
O	1364	1365	,	,	,	O
O	1366	1369	and	and	CC	O
O	1370	1372	BC	BC	NN	B-NP
O	1372	1373	)	)	)	O
O	1374	1376	of	of	IN	B-PP
O	1377	1384	disease	disease	NN	B-NP
O	1385	1396	progression	progression	NN	I-NP
O	1396	1397	.	.	.	O

O	1398	1405	RESULTS	RESULTS	NNS	B-NP
O	1405	1406	:	:	:	O
O	1407	1410	The	The	DT	B-NP
O	1411	1421	expression	expression	NN	I-NP
O	1422	1428	ofVEGF	ofVEGF	NN	I-NP
O	1429	1436	protein	protein	NN	I-NP
O	1437	1440	was	be	VBD	B-VP
O	1441	1445	most	most	RBS	B-ADJP
O	1446	1456	pronounced	pronounced	JJ	I-ADJP
O	1457	1459	in	in	IN	B-PP
O	1460	1462	AP	AP	NN	B-NP
O	1463	1464	(	(	(	O
O	1464	1469	ANOVA	ANOVA	NN	B-NP
O	1469	1470	,	,	,	O
O	1471	1472	p	p	NN	B-NP
O	1472	1473	=	=	SYM	B-VP
O	1473	1474	0	0	CD	B-NP
O	1474	1475	.	.	.	O
O	1475	1478	033	033	CD	B-NP
O	1478	1479	)	)	)	O
O	1479	1480	.	.	.	O

O	1481	1484	The	The	DT	B-NP
O	1485	1490	level	level	NN	I-NP
O	1491	1493	of	of	IN	B-PP
O	1494	1498	VEGF	VEGF	NN	B-NP
O	1499	1509	expression	expression	NN	I-NP
O	1510	1520	correlated	correlate	VBD	B-VP
O	1521	1530	inversely	inversely	RB	B-ADVP
O	1531	1535	with	with	IN	B-PP
O	1536	1539	the	the	DT	B-NP
O	1540	1546	degree	degree	NN	I-NP
O	1547	1549	of	of	IN	B-PP
B-Pathological_formation	1550	1562	splenomegaly	splenomegaly	NN	B-NP
O	1563	1564	(	(	(	O
O	1564	1571	Pearson	Pearson	NNP	B-NP
O	1571	1572	,	,	,	O
O	1573	1574	r	r	NN	B-NP
O	1574	1575	=	=	SYM	B-VP
O	1575	1576	-	-	SYM	B-NP
O	1576	1577	0	0	CD	I-NP
O	1577	1578	.	.	SYM	I-NP
O	1578	1581	400	400	CD	I-NP
O	1581	1582	,	,	,	O
O	1583	1584	p	p	NN	B-NP
O	1584	1585	=	=	SYM	B-VP
O	1585	1586	0	0	CD	B-NP
O	1586	1587	.	.	SYM	I-NP
O	1587	1590	011	011	CD	I-NP
O	1590	1591	)	)	)	O
O	1591	1592	.	.	.	O

O	1593	1597	High	High	JJ	B-NP
O	1598	1608	expression	expression	NN	I-NP
O	1609	1611	of	of	IN	B-PP
O	1612	1616	VEGF	VEGF	NN	B-NP
O	1617	1627	correlated	correlate	VBD	B-VP
O	1628	1632	with	with	IN	B-PP
O	1633	1634	a	a	DT	B-NP
O	1635	1642	shorter	short	JJR	I-NP
O	1643	1650	overall	overall	JJ	I-NP
O	1651	1659	survival	survival	NN	I-NP
O	1660	1661	(	(	(	O
O	1661	1664	log	log	NN	B-NP
O	1665	1669	rank	rank	NN	I-NP
O	1669	1670	,	,	,	O
O	1671	1672	p	p	NN	B-NP
O	1672	1673	=	=	SYM	B-VP
O	1673	1674	0	0	CD	B-NP
O	1674	1675	.	.	SYM	I-NP
O	1675	1678	042	042	CD	I-NP
O	1678	1679	)	)	)	O
O	1679	1680	.	.	.	O

O	1681	1691	CONCLUSION	CONCLUSION	NN	B-NP
O	1691	1692	:	:	:	O
O	1693	1714	Immunohistochemically	Immunohistochemically	RB	B-NP
O	1715	1724	confirmed	confirm	VBN	I-NP
O	1725	1737	significance	significance	NN	I-NP
O	1738	1740	of	of	IN	B-PP
O	1741	1744	the	the	DT	B-NP
O	1745	1755	expression	expression	NN	I-NP
O	1756	1758	of	of	IN	B-PP
O	1759	1763	VEGF	VEGF	NN	B-NP
O	1764	1766	in	in	IN	B-PP
O	1767	1777	dependence	dependence	NN	B-NP
O	1778	1780	of	of	IN	B-PP
O	1781	1784	the	the	DT	B-NP
B-Cancer	1785	1788	CML	CML	NN	I-NP
O	1789	1794	stage	stage	NN	I-NP
O	1795	1800	could	could	MD	B-VP
O	1801	1803	be	be	VB	I-VP
O	1804	1806	of	of	IN	B-PP
O	1807	1815	clinical	clinical	JJ	B-NP
O	1816	1826	importance	importance	NN	I-NP
O	1827	1829	in	in	IN	B-PP
O	1830	1838	deciding	decide	VBG	B-VP
O	1839	1841	on	on	IN	B-PP
O	1842	1845	the	the	DT	B-NP
O	1846	1852	timing	timing	NN	I-NP
O	1853	1860	therapy	therapy	NN	I-NP
O	1860	1861	.	.	.	O

O	1862	1867	These	These	DT	B-NP
O	1868	1872	data	datum	NNS	I-NP
O	1873	1880	suggest	suggest	VBP	B-VP
O	1881	1885	that	that	IN	B-SBAR
O	1886	1890	VEGF	VEGF	NN	B-NP
O	1891	1896	plays	play	VBZ	B-VP
O	1897	1898	a	a	DT	B-NP
O	1899	1903	role	role	NN	I-NP
O	1904	1906	in	in	IN	B-PP
O	1907	1910	the	the	DT	B-NP
O	1911	1918	biology	biology	NN	I-NP
O	1919	1921	of	of	IN	B-PP
B-Cancer	1922	1925	CML	CML	NN	B-NP
O	1926	1929	and	and	CC	O
O	1930	1934	that	that	IN	B-SBAR
O	1935	1939	VEGF	VEGF	NN	B-NP
O	1940	1950	inhibitors	inhibitor	NNS	I-NP
O	1951	1957	should	should	MD	B-VP
O	1958	1960	be	be	VB	I-VP
O	1961	1973	investigated	investigate	VBN	I-VP
O	1974	1976	in	in	IN	B-PP
B-Cancer	1977	1980	CML	CML	NN	B-NP
O	1980	1981	.	.	.	O

